| Features | |
| Active substance | Apremilast |
| Also known as | CC-10004 |
| Blood pressure | No significant effects on blood pressure |
| Chemical name | N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide |
| Dosage (medical) | 30 mg twice daily after initial titration |
| Dosage (sports) | Not applicable |
| Effects | Reduces inflammation by inhibiting PDE4, an enzyme involved in the process of inflammatory response |
| Formula | C22H24N2O7S |
| Half-life | Approximately 6-9 hours |
| Hepatotoxicity | Minimal to no hepatotoxicity reported |
| Lab Test | Monitoring is not typically required for liver enzymes unless under specific medical advice |
| Main action | Anti-inflammatory |
| Side effects | Diarrhea, nausea, headache, upper respiratory tract infection, weight loss |
| Storage conditions | Store at 20В°C to 25В°C (68В°F to 77В°F), excursions permitted between 15В°C to 30В°C (59В°F to 86В°F) |
| Strength | 30mg |
| Substance class | Phosphodiesterase 4 (PDE4) inhibitor |
| Trade name | Otezla |
| Use in sports | Not typically used in sports, lacks performance-enhancing properties |
| Water Retention | No significant effect |
| Manufacturer | Glenmark Pharmaceuticals Ltd. |
| Packing | 10 tabs/blister |